IMAB362

IMAB362 is a monoclonal antibody that is being studied in the treatment of certain types of cancer. It is made in the laboratory and can locate and bind to substances in the body, including cancer cells. IMAB362 binds to a protein called CLDN18.2, which is found on certain cancer cells. It may help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immunotoxin.

Mechanism of Action[edit | edit source]

IMAB362 is a chimeric monoclonal antibody that targets the CLDN18.2 antigen, a protein that is overexpressed in certain types of gastrointestinal cancer. By binding to this antigen, IMAB362 may stimulate the immune system to attack and kill the cancer cells that express CLDN18.2.

Clinical Trials[edit | edit source]

IMAB362 is currently being studied in clinical trials for the treatment of gastric cancer and gastroesophageal junction cancer. Preliminary results have shown promise, with some patients experiencing a reduction in tumor size and improved survival rates.

Side Effects[edit | edit source]

As with all chemotherapy, IMAB362 can cause side effects. These may include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include infusion reactions, low blood counts, and infections.

See Also[edit | edit source]

IMAB362 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.